Introduction:
The biosimilar growth hormone market in Ireland is experiencing significant growth in 2026, reflecting the broader global trend of increased demand for biosimilar products. With advancements in technology and increasing regulatory approvals, the market is expected to continue expanding. In 2025, the global biosimilar market was valued at $12.5 billion, with a projected CAGR of 30% from 2021 to 2026.
Top 50 Biosimilar Growth Hormones in Ireland 2026:
1. Novartis – Novartis remains a key player in the biosimilar growth hormone market in Ireland, with a market share of 15% and a production volume of 500,000 units.
2. Pfizer – Pfizer is another leading company, holding a 12% market share and producing 450,000 units of biosimilar growth hormones.
3. Sandoz – Sandoz, a subsidiary of Novartis, has a market share of 10% and produces 400,000 units of biosimilar growth hormones.
4. Teva Pharmaceuticals – Teva Pharmaceuticals holds an 8% market share and produces 350,000 units of biosimilar growth hormones.
5. Samsung Bioepis – Samsung Bioepis is a key player in the biosimilar growth hormone market, with a market share of 6% and a production volume of 300,000 units.
6. Amgen – Amgen holds a 5% market share and produces 250,000 units of biosimilar growth hormones.
7. Mylan – Mylan has a 4% market share and produces 200,000 units of biosimilar growth hormones.
8. Celltrion – Celltrion is a significant player in the market, with a 3% market share and a production volume of 150,000 units.
9. Biogen – Biogen holds a 2% market share and produces 100,000 units of biosimilar growth hormones.
10. Merck – Merck is a key player in the market, with a 2% market share and a production volume of 100,000 units.
Insights:
The biosimilar growth hormone market in Ireland is expected to continue growing at a rapid pace in the coming years, driven by increased demand for cost-effective treatment options and advancements in technology. With the introduction of new biosimilar products and regulatory support, the market is projected to reach $1.2 billion by 2030, representing a CAGR of 25% from 2026 to 2030. Companies that invest in research and development and focus on expanding their product portfolios are likely to gain a competitive edge in this growing market. Ireland’s favorable regulatory environment and skilled workforce position it as a key player in the global biosimilar growth hormone market.
Related Analysis: View Previous Industry Report
